A key goal for the future is to influence specific mediators that control insulin production by targeting changes in the microbial composition of intestinal segments, or to interfere with appetite and eating preferences for the development of therapeutics for obesity and T2D. The gene discussed is INS; the disease is type 2 diabetes mellitus.